Literature DB >> 18558789

Perioperative safety of aprotinin in coronary artery bypass graft surgery: is there life after BART?

John G Augoustides1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18558789     DOI： 10.2165/00002018-200831070-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  19 in total

1.  Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?

Authors:  Dean Fergusson; Kathleen Cranley Glass; Brian Hutton; Stan Shapiro
Journal:  Clin Trials       Date:  2005       Impact factor: 2.486

2.  The risk associated with aprotinin in cardiac surgery.

Authors:  Dennis T Mangano; Iulia C Tudor; Cynthia Dietzel
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

3.  Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.

Authors:  Jeremiah R Brown; Nancy J O Birkmeyer; Gerald T O'Connor
Journal:  Circulation       Date:  2007-05-28       Impact factor: 29.690

4.  Case 1-2008. One institution's decreasing use of aprotinin during cardiac surgery in 2006.

Authors:  Zaneta Y Strouch; Mark A Chaney; John G T Augoustides; Bruce D Spiess
Journal:  J Cardiothorac Vasc Anesth       Date:  2008-02       Impact factor: 2.628

5.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.

Authors:  Dean A Fergusson; Paul C Hébert; C David Mazer; Stephen Fremes; Charles MacAdams; John M Murkin; Kevin Teoh; Peter C Duke; Ramiro Arellano; Morris A Blajchman; Jean S Bussières; Dany Côté; Jacek Karski; Raymond Martineau; James A Robblee; Marc Rodger; George Wells; Jennifer Clinch; Roanda Pretorius
Journal:  N Engl J Med       Date:  2008-05-14       Impact factor: 91.245

6.  The aprotinin story--is BART the final chapter?

Authors:  Wayne A Ray; C Michael Stein
Journal:  N Engl J Med       Date:  2008-05-14       Impact factor: 91.245

7.  The demise of aprotinin: our share of the blame.

Authors:  Thoralf M Sundt
Journal:  J Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 5.209

8.  High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin.

Authors:  Wulf Dietrich; Raimund Busley; Monika Kriner
Journal:  Anesth Analg       Date:  2006-11       Impact factor: 5.108

9.  The effect of aprotinin on outcome after coronary-artery bypass grafting.

Authors:  Andrew D Shaw; Mark Stafford-Smith; William D White; Barbara Phillips-Bute; Madhav Swaminathan; Carmelo Milano; Ian J Welsby; Solomon Aronson; Joseph P Mathew; Eric D Peterson; Mark F Newman
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

10.  Influence of ultra-low dose Aprotinin on thoracic surgical operations: a prospective randomized trial.

Authors:  Efstratios Apostolakis; Nikolaos Panagopoulos; Efstratios N Koletsis; James Crockett; Helen Stamou-Kouki; Efrosini Sourgiadaki; Kriton Filos; Dimitrios Dougenis
Journal:  J Cardiothorac Surg       Date:  2008-03-24       Impact factor: 1.637
View more
  3 in total

1.  A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Authors:  Peter G M Mol; Sabine M J M Straus; Sigrid Piening; Jonie T N de Vries; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

2.  Cardiopulmonary Bypass, Inflammation and How to Defy it: Focus on Pharmacological Interventions.

Authors:  Ali Dabbagh; Samira Rajaei; Ayad Bahadori Monfared; Ali Asghar Keramatinia; Korosh Omidi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

Review 3.  Risk factors for postoperative respiratory mortality and morbidity in patients undergoing coronary artery bypass grafting.

Authors:  Samira Rajaei; Ali Dabbagh
Journal:  Anesth Pain Med       Date:  2012-09-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.